循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 Ⅲ章　プレシジョン・メディシン時代における循環器系の予防・診断・治療技術

腫瘍循環器領域におけるバイオマーカーの現状

著者： 中川仁¹ 斎藤能彦¹

所属機関： ¹奈良県立医科大学循環器内科

ページ範囲：P.594 - P.599

Point
・心筋障害を反映するトロポニンと，心収縮能低下を反映するBNPが有用なバイオマーカーである．
・2種類のバイオマーカーを組み合わせて早期診断，早期治療につなげることが重要である．

参考文献

1) Pudil R, Mueller C, Čelutkienė J, et al:Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies:a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22:1966-1983, 2020

2) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology（ESC）. Eur J Heart Fail 19:9-42, 2017

3) Cardinale D, Sandri MT, Colombo A, et al:Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754, 2004

4) Auner HW, Tinchon C, Linkesch W, et al:Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82:218-222, 2003

5) Kremer LC, van der Pal HJ, Offringa M, et al:Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children:a systematic review. Ann Oncol 13:819-829, 2002

6) Cardinale D, Colombo A, Sandri MT, et al:Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481, 2006

7) Cardinale D, Ciceri F, Latini R, et al:Anthracycline-induced cardiotoxicity:A multicenter randomised trial comparing two strategies for guiding prevention with enalapril:The International CardioOncology Society-one trial. Eur J Cancer 94:126-137, 2018

8) Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al:Carvedilol for prevention of chemotherapy-related cardiotoxicity:The CECCY trial. J Am Coll Cardiol 71:2281-2290, 2018

9) Skovgaard D, Hasbak P, Kjaer A:BNP predicts chemotherapy-related cardiotoxicity and death:comparison with gated equilibrium radionuclide ventriculography. PloS One 9:e96736, 2014

10) Daugaard G, Lassen U, Bie P, et al:Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87-93, 2005

11) Riddell E, Lenihan D:The role of cardiac biomarkers in cardio-oncology. Curr Probl Cancer 42:375-385, 2018

12) Cardinale D, Colombo A, Torrisi R, et al:Trastuzumab-induced cardiotoxicity:clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916, 2010

13) Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al:Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer:A Randomized Clinical Trial. JAMA Oncol 2:1030-1037, 2016

14) Gulati G, Heck SL, Ree AH, et al:Prevention of cardiac dysfunction during adjuvant breast cancer therapy（PRADA）:a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671-1680, 2016

15) Zardavas D, Suter TM, Van Veldhuisen DJ, et al:Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab:a Herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35:878-884, 2017

16) Mahmood SS, Fradley MG, Cohen JV, et al:Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755-1764, 2018

17) Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al:Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation 140:31-41, 2019